Article Text

Download PDFPDF
Letter
Assessment of liver fibrosis with the gamma-glutamyl transpeptidase to platelet ratio: a multicentre validation in patients with HBV infection
  1. Xiao-Jie Lu1,2,
  2. Xiu-Hui Li3,
  3. Zhao-Xin Yuan4,5,
  4. Hai-Ying Sun5,
  5. Xiao-Chen Wang1,2,
  6. Xiaolong Qi6,
  7. Xin Zhang7,
  8. Beicheng Sun1,2
  1. 1 Department of Liver Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  2. 2 Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of NanjingUniversity Medical School, Nanjing, China
  3. 3 Department of Integrated Traditional Chinese Medicine and Western Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, China
  4. 4 Changchun Medical College, Changchun, Jilin, China
  5. 5 Department of Hepatology, Hepatobiliary Disease Hospital of Jilin Province, Changchun, Jilin, China
  6. 6 Guangdong Provincial Research Center for Liver Fibrosis, Institute of Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou, China
  7. 7 Department of Medical Imaging, The Fourth Hospital of Huai’an, Huai’an, China
  1. Correspondence to Dr Beicheng Sun, Department of Liver Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China; sunbc{at}njmu.edu.cn and Dr Xin Zhang, Department of Medical Imaging, The Fourth Hospital of Huai’an, Huai’an, China; 973306782{at}qq.com

Statistics from Altmetric.com

We read with interest the study by Lemoine et al 1 in which the gamma-glutamyl transpeptidase (GGT) to platelet ratio (GPR) was developed to stage fibrosis in patients with chronic hepatitis B (CHB). This study concluded that GPR is more accurate than the aspartate aminotransferase to platelet ratio index (APRI) and Fib-4 to stage liver fibrosis in patients with CHB. As China is a highly endemic area of CHB with estimated >74 million hepatitis B surface antigen (HBsAg)-positive patients,2 3 we conducted this multicentre study to validate the diagnostic performance of GPR in Chinese patients with CHB.

Treatment-naïve patients with positive HBsAg who underwent liver biopsy, Fibroscan (FS402, Echosens, France) and blood tests were included from three centres (Huai’an Fourth People’s Hospital, Huai’an, China (January 2012–April 2016), Beijing You-An Hospital, Capital Medical University, Beijing, China (January 2014–June 2016) and Hepatology Hospital of Jilin Province, Jilin, China (January 2014–October 2016)). The …

View Full Text

Footnotes

  • X-JL, X-HL and Z-XY contributed equally.

  • Contributors X-JL and BS led the research programme; X-JL and XZ conceived the idea; XZ, X-HL and Z-XY were principal investigators of participant centres; H-YS, X-CW and XQ collected and analysed the data; X-JL wrote the manuscript and BS made critical revisions.

  • Funding This study was supported by the National Key Research and Development Program of China under Grant no 2016YFC0905900 to BS and the Natural Science Foundation of China (NO.81772596 to X-JL).

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval Ethics Committee of Huai’an Fourth People’s Hospital (Huai’an, China); Ethics Committee of Beijing You-An Hospital, Capital Medical University (Beijing, China); Ethics Committee of Hepatology Hospital of Jilin Province (Jilin, China).

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles